Thus, targeting GPRC6A activation represents a potential paradigm shifting opportunity to make significant strides in treating and preventing T2DM by simultaneously targeting abnormalities in β-cells, hepatocytes and skeletal muscle as well as stimulating an ensemble of metabolically active hormones [5]. Here, GPRC6A is linked to type 2 diabetes mellitus.